论文部分内容阅读
磷脂酰肌醇-3激酶(PI3K)信号通路的过度激活与包括滤泡淋巴瘤(FL)在内的多种血液系统恶性肿瘤的发生、发展密切相关。PI3K通过激活下游多个信号通路靶点，参与调节细胞生长、增殖、分化、迁移及凋亡。PI3K抑制剂通过抑制PI3K，阻断PI3K/AKT/mTOR信号通路，抑制血液系统恶性肿瘤的发生、发展。近年来，PI3K抑制剂成为相关领域研究热点，多种类型PI3K抑制剂已经获批上市或者正在进行临床试验，其对复发/难治性非霍奇金淋巴瘤(NHL)，尤其是FL的治疗已取得重要进展。笔者拟就PI3K抑制剂在复发/难治性FL中有效性及安全性的最新研究进展进行阐述。“,”Over-activation of phosphatidylinositol-3 kinase (PI3K) signaling pathway is closely related to the occurrence and development of many hematological malignant tumors including follicular lymphoma (FL). PI3K regulates cell growth, proliferation, survival, migration and differentiation by activating several targets in down stream signaling pathways. PI3K inhibitors can influence the occurrence and development of hematological malignant tumors by inhibiting PI3K and blocking the PI3K/AKT/mTOR signaling pathways. PI3K inhibitors have become a new research hot spot in recent years. The variety types of PI3K inhibitors have been marketed or entered clinical trials and have shown considerable progresses in treatment of relapsed/refractory non-Hodgkin lymphoma (NHL), especially FL. In this review, recent advances in the efficacy and safety of PI3K inhibitors in treatment of relapsed/refractory FL are summarized.